- Lipella Pharmaceuticals (LIPO, Financial) to present LP-10 data for Oral Lichen Planus at international conference.
- Phase 2a trial shows statistically significant clinical improvements with LP-10.
- Final topline results expected in Q2 2025.
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company, announced that its abstract on LP-10, a treatment for Oral Lichen Planus (OLP), has been accepted for podium presentation at the 2025 joint international meeting of the American Academy of Oral Medicine (AAOM) and European Association of Oral Medicine (EAOM) in Las Vegas from May 14-17. The presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute on May 15.
The abstract, titled "Liposomal Tacrolimus (LP-10) Oral Rinse for the Treatment of Oral Lichen Planus: Topline Analysis of a Phase 2a Multicenter Dose-Ranging Trial," reports the results of an ongoing trial evaluating a liposomal formulation of tacrolimus. This formulation aims to treat the chronic inflammatory condition that affects the oral mucosa, causing pain and ulcerations. The trial results demonstrate clinically meaningful improvements after four weeks of treatment, with statistically significant reductions in inflammation and ulcerative lesions in some patients.
Dr. Michael Chancellor, Chief Medical Officer and Co-Founder of Lipella, highlighted that the effects of LP-10 were most notable at the end of the treatment period, underscoring the clinical relevance of its localized activity. The trial measured dose levels of tacrolimus at 0.25 mg, 0.5 mg, and 1.0 mg, with the 0.5 mg cohort showing significant improvement at Week 4.
Lipella is committed to addressing significant unmet medical needs, as OLP currently has no FDA-approved treatments. Final topline results from the fully enrolled trial are anticipated in the second quarter of 2025, which will further elucidate the drug's efficacy and safety profile.
